EUVIMEDEUVIMED entdecken
Open Access

Optimizing breast core needle biopsy biomarker throughput using an AI ‐based workflow

Frederik Deman iD, Glenn Broeckx iD, Quentin Degotte, Vasiliki Siozopoulou iD, Maria Del Carmen Tavares, Sabine Declercq, Roberto Salgado iD, Amélie Dendooven iD

Histopathology · 2026-09 · 89 (3) · 495-503

DOI: 10.1111/his.70181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 20.05.2026. Verfasst von Frederik Deman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Ziekenhuis aan de Stroom (ZAS), Antwerp, Belgium. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Workflow, Artificial Intelligence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the feasibility, appropriate relevance and impact on turnaround time (TAT) of an AI‐supported workflow in which AI, integrated in the Laboratory Information System (LIS) as well as in the daily workflow, autonomously triggers breast biomarker testing (ER, PR, HER2, Ki‐67) for breast core needle biopsies with a high AI‐based likelihood of invasive breast cancer. Methods and results This retrospective, unicentric implementation study utilized an AI system (IBEX™ Breast) to stratify H&E slides. For cases classified as ‘high likelihood for invasive carcinoma’, the LIS automatically ordered the standard biomarker panel (ER, PR, HER2 and Ki67), bypassing initial pathologist slide reading. The TAT was measured from the moment of the case assignment to both the availability of IHC staining (TAT tech ) and the moment of reporting of the biomarkers (TAT clin ). A pre‐implementation phase (December 2024–May 2025; June 2024–November 2025) was compared with a post‐implementation phase (June 2025–November 2025). The appropriate relevance of the automated ordering was assessed by evaluating the AI‐initiated testing and the relevance of the ordered stains for the final diagnosis. Implementation of the AI‐enhanced workflow resulted in a statistically significant reduction in TAT tech from approximately 32 h to 23 h, (−30%, P < 0.01) and TAT clin reduction of approximately 1 working day ( P ≤ 0.03) demonstrating that technical gains translate directly into faster biomarker reporting. Diagnostic accuracy was maintained throughout, with no unnecessary stains triggered by the system.

Conclusions

Integrated, LIS‐embedded AI in the daily workflow significantly optimizes breast cancer biomarker turnaround time without compromising the diagnostic process of a pathology laboratory. This demonstrates the transformative potential of AI to enhance laboratory efficiency and support more rapid patient‐centred oncologic care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorWorkflowArtificial IntelligenceHumansFemaleRetrospective StudiesBiopsy, Large-Core Needle

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Ziekenhuis aan de Stroom (ZAS), Antwerp, Belgium.
  • Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
  • Center for Brain Disease, Switch Lab, VIB-KU Leuven Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Centre for Oncological Research (CORE), MIPPRO, Faculty of Medicine, Antwerp University, Antwerp, Belgium.
  • Division of Research, Peter mac Callum Cancer Centre, Melbourne, Australia.
  • Department of Pathology, University Hospital Ghent, Ghent, Belgium.

ORCID-Profile: Frederik Deman, Glenn Broeckx, Vasiliki Siozopoulou, Roberto Salgado, Amélie Dendooven

Zitieren

APA

Deman, F., Broeckx, G., Degotte, Q., Siozopoulou, V., Del Carmen Tavares, M., Declercq, S., Salgado, R., & Dendooven, A. (2026). Optimizing breast core needle biopsy biomarker throughput using an AI ‐based workflow. Histopathology, 89(3), 495-503. https://doi.org/10.1111/his.70181

Vancouver

Deman F, Broeckx G, Degotte Q, Siozopoulou V, Del Carmen Tavares M, Declercq S, et al. Optimizing breast core needle biopsy biomarker throughput using an AI ‐based workflow. Histopathology. 2026;89(3):495-503. doi:10.1111/his.70181

BibTeX
@article{Deman2026,
  author = {Deman, Frederik and Broeckx, Glenn and Degotte, Quentin and Siozopoulou, Vasiliki and Del Carmen Tavares, Maria and Declercq, Sabine and Salgado, Roberto and Dendooven, Amélie},
  title = {Optimizing breast core needle biopsy biomarker throughput using an AI ‐based workflow},
  journal = {Histopathology},
  year = {2026},
  volume = {89},
  number = {3},
  pages = {495--503},
  doi = {10.1111/his.70181}
}
Kostenlos starten →